Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.
Unknown authors
Topics & Concepts
GolimumabUlcerative colitisMedicineDouble blindRandomized controlled trialInternal medicineTumor necrosis factor alphaPlaceboAlternative medicineAdalimumabDiseasePathologyInflammatory Bowel DiseaseMicroscopic ColitisHelicobacter pylori-related gastroenterology studies